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Increasing numbers of reports have documented the
ergence of Escherichia coli capable of producing broad-
ctrum b-lactamases. This is signiﬁcant since the b-
am antimicrobials are of therapeutic importance in
humans and many domestic animals. Furthermore, many
isolates are resistant to additional antimicrobial classes
and are therefore multidrug-resistant (MDR).
Carriage of ESBL- and AmpC-producing E. coli has been
documented in many species (Bortolaia et al., 2011).
Antimicrobial use has been reported as a risk factor
(Damborg et al., 2011, 2012; Maddox et al., 2012) and there
is also evidence of sharing of organisms between species
living in close proximity to each other (Dolejska et al.,
2011). Considering the physical closeness in which many
humans live with their pet companions, sharing of these
organisms between humans and pets could pose a
signiﬁcant mutual risk.
 T I C L E I N F O
le history:
ived 29 July 2013
ived in revised form 2 January 2014
pted 3 January 2014
ords:
erichia coli
mid-mediated AmpC
ary tract infection
tidrug-resistant
ctamase
A B S T R A C T
Multidrug-resistant Escherichia coli is an emerging clinical challenge in domestic species.
Treatment options in many cases are limited. This study characterized MDR E. coli isolates
from urinary tract infections in dogs, collected between 2002 and 2011. Isolates were
evaluated in terms of b-lactamase production, phylogenetic group, ST type, replicon type
and virulence marker proﬁle. Comparisons were made with antibiotic susceptible isolates
also collected from dogs with urinary tract infections. AmpC b-lactamase was produced in
67% of the MDR isolates (12/18). Of these, 8 could be speciﬁcally attributed to the CMY-2
gene. None of the isolates tested in either group expressed ESBLs. Phylo-group distribution
was as expected in the susceptible isolates, with an over representation of the pathogenic
B2 phylo-group (67%). In contrast, the phylogenetic background for the MDR group was
mixed, with representation of commensal phylo-groups A and B1. The B2 phylo-group
represented the smallest proportion (A, B1, B2 or D was 28%, 22%, 11% and 33%,
respectively). Virulence marker proﬁles, evaluated using Identibac1 microarray,
discriminated between the two groups. Marker sequences for a core panel of virulence
determinants were identiﬁed in most of the susceptible isolates, but not in most of the
MDR isolates. These ﬁndings indicate that for MDR isolates, plasmid-mediated AmpC is an
important resistance mechanism, and while still capable of causing clinical disease, there
is evidence for a shift towards phylogenetic groups of reduced inferred virulence potential.
There was no evidence of zoonotic potential in either the susceptible or MDR urinary tract
isolates in this study.
 2014 The Authors. Published by Elsevier B.V. 
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documented in humans. Initially the pattern was of
hospital-acquired infection but community-acquired
infection has become increasingly important. ESBL E. coli
are associated with a variety of clinical diseases, in
particular urinary tract infections, neonatal septicaemia
and wound infections (Ben-Ami et al., 2009; Pitout, 2010).
Reports of similar clinical disease associated with AmpC-
producing E. coli are far fewer than those pertaining to
ESBLs, however these also appear to be an emerging
problem (Oteo et al., 2010).
Although most animal studies have focused on the
zoonotic risk posed by carriage, there are increasing
reports demonstrating the involvement of these organisms
in clinical disease in domestic species in a variety of
locations including Europe, North America, Asia and
Australia. For example, in the United States AmpC (CMY-
2) and ESBL-producing E. coli (O’Keefe et al., 2010; Sanchez
et al., 2002; Shaheen et al., 2011) have been reported from
canine clinical isolates. Clinical disease associated with
AmpC-producing E. coli in dogs in Australia, was ﬁrst
reported in 2006 (Sidjabat et al., 2006). More recently, a
survey of clinical isolates from dogs and horses in the
Netherlands demonstrated a 2% prevalence of ESBL and
AmpC-producing isolates (Dierikx et al., 2012).
The aim of this study was to evaluate the association of
ESBL or AmpC production with multidrug-resistant E. coli
isolated from clinical cases of urinary tract infection in
dogs from a local patient population, over a period of time
ranging from 2002 to 2011. Isolates were further
characterized in terms of phylogenetic grouping, sequence
type and virulence genotype. Plasmid replicon typing was
also performed to identify the type and diversity of
plasmids involved. Comparisons were made to a group of
susceptible E. coli isolates, also associated with canine
urinary tract infection and collected over a similar time
frame.
2. Materials and methods
2.1. Source of clinical isolates
All 15 susceptible and 17/18 MDR isolates were
identiﬁed in clinical cases seen at the Hospital for Small
Animals, University of Edinburgh. One MDR isolate (R3)
came from a local practice serviced by the University of
Edinburgh’s diagnostic microbiology service.
2.2. E. coli identiﬁcation
A total of 33 clinical isolates from canine urinary tract
infections were cultured on Blood and MacConkey agar.
Any lactose fermenting colonies were conﬁrmed as E. coli
utilizing biochemical testing (API 10S1 strip bioMerieux).
2.3. Antimicrobial susceptibility testing
Susceptibility testing was performed using the disc
diffusion method in accordance with Clinical Laboratory
Standards Institute (CLSI) guidelines. The following discs
amoxicillin clavulanate (30 mg); cephalexin (30 mg); gen-
tamicin (10 mg); tetracycline (10 mg); cefotaxime (30 mg).
All discs were sourced from Mast group Ltd.
2.4. Control strains
The following control strains were utilized in both the
phenotypic combination disc testing and for polymerase
chain reaction. ATCC 25922TM (negative control); ATCC BA-
199TM (SHV-3 positive control); NCTC 13353TM (CTX-M-15
positive control), and NCTC 13351TM (TEM-3 positive
control).
2.5. Combination disc method for plasmid-mediated AmpC
and ESBL detection
A commercially available AmpC and ESBL detection set
(Mast group Ltd) was utilized. This comprised a set of 4
discs containing cefpodoxime plus or minus AmpC and
ESBL inhibitors. Interpretation was made following the
manufacturer’s instructions.
2.6. PCR for ESBL and AmpC gene detection
DNA from single colonies of each isolate was prepared
using the lysis method as previously described (Pe´rez-
Pe´rez and Hanson, 2002). Primers for the genes blaTEM,
blaSHV, blaCTX, blaCMY-1 group, blaCMY-2 group, blaOXA-1
group and blaOXA-2 group were derived from a previously
established assay (Hasman et al., 2005). For additional
detection of AmpC b-lactamase genes, multiplex PCR was
performed on all samples using the methodology and
primers previously described (Pe´rez-Pe´rez and Hanson,
2002). PCR products were electrophoresed in a 1% agarose
gel, gel bands were excised, and sequences were compared
to the NCBI database to conﬁrm identity.
2.7. Multiplex PCR phylogenetic grouping of clinical isolates
DNA from single colonies was prepared using the
Qiagen DNeasy blood and tissue extraction kit according to
the manufacturer’s instructions (Qiagen, UK). Multiplex
PCR methodology was employed to assign the clinical
isolates to one of four phylogenetic groups (A, B1, B2 or D).
Primers and methodology have been described previously
(Doumith et al., 2012).
2.8. PCR-based plasmid replicon typing of clinical isolates
DNA was isolated as described above for the phyloge-
netic grouping. Methodology involved the use of 8
multiplex reactions in a commercial kit (Diatheva, Italy)
based on methodology described previously (Carattoli
et al., 2005).
2.9. Identibac1 microarray analysis
A microarray assay developed and carried out by the
Animal Health Veterinary Laboratories Agency (AHVLA)
was used (Batchelor et al., 2008). The microarray contained
a selection of oligonucleotide probes mapping to a range ofwere used: Co-trimoxazole (25 mg); ciproﬂoxacin (1 mg);
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ions resulting in signal intensities greater than 0.4 were
sidered positive indicating the presence of the gene.
. MLST methodology
DNA was extracted using a DNeasy extraction kit
agen) and performed as to the manufacturer’s instruc-
s. Sequencing of the DNA was carried out on an
mina MiSeq (ARK Genomics). Raw sequence reads were
ned to two reference sequences, E. coli ABU83972 and
coli MG1655 (Accession numbers NC_017631.1 and
000913.2), using BWA and Samtools (Li and Durbin,
9). Sequence type calling (for multi-locus sequence
ing) was performed using SRST (Inouye et al., 2012).
ates which could not be typed using SRST were called
nually using sequences mapped to MG1655. Sequences
ning to the MLST genes in MG1655 were extracted
ng VCFtools (Danecek et al., 2011) and Extractseq, (Rice,
0) and entered manually into the MLST Database,
ted by University College Cork (http://mlst.ucc.ie/mlst/
/Ecoli).
. Statistical methods
Comparisons were tested using Fisher’s exact test. The
erion for statistical signiﬁcance was taken to be
 0.05.
esults
 Culture and sensitivity
Between 2002 and 2011, 18 E. coli isolates associated
h urinary tract infections (UTIs) in 16 dogs were
ntiﬁed as multidrug-resistant (MDR). Results of culture
and sensitivity testing for the MDR isolates (R1-16) are
displayed in Table 1. Two of the dogs had recurrent UTI
infection. One case recurred 1 month later (R16a and b)
and the second case 6 months later (R11a and b). The
criterion used to make the MDR determination was
resistance to 3 or more classes of antimicrobial on
routine culture and sensitivity testing. All MDR isolates
were resistant to amoxicillin clavulanate and tetracy-
cline, 83% (15/18) were resistant to cephalexin, 78% (14/
18) were resistant to co-trimoxazole, 56% (10/18) were
resistant to ciproﬂoxacin, 22% (4/18) were resistant to
gentamicin and 67% (12/18) were resistant to the 3rd
generation cephalosporin cefotaxime. The latter was
used as an indicator of broad-spectrum b-lactamase
production.
For comparison, 15 E. coli isolates were selected for
study, based on the criteria that they were susceptible to
all 7 antimicrobial classes listed above. These isolates were
associated with urinary tract infections in dogs.
3.2. AmpC b-lactamase phenotype and genotype
To identify the contribution of either ESBL or AmpC b-
lactamases to the MDR phenotype, all isolates (both MDR
and susceptible groups) were tested using the 4 disc test as
described in materials and methods. All susceptible
isolates were negative (data not shown). A total of 67%
(12/18) of MDR isolates were positive for AmpC produc-
tion. ESBL production was not detected.
Using ampC multiplex PCR, 9/12 isolates phenotypi-
cally AmpC positive were genotypically positive for
pAmpC (CITM group). Further simplex PCR identiﬁed 8
of these to be speciﬁcally associated with the CMY-2 gene.
Identibac1microarray also detected a CMY gene signal in
8/9 isolates tested (isolates relate to R1–R7, R9 and R10 in
Table 1).
le 1
mary of phenotypic and genotypic characterization of the MDR E. coli isolates.
late Isolation date (month/year) Resistance pattern 3rd Gen AmpC Pheno pAmpC PCR Phylo ST Replicon type
 9/2006 AMC CEF COT CIP TET R + + A 10 FII I1
 1/2008 AMC CEF COT TET R + + n/t 46 FII I1
 9/2010 AMC CEF COT CIP TET R + + A 744 FII I1
 10/2010 AMC CEF TET R + + D 648 FII I1
 3/2010 AMC CEF TET R + + D 963 FII I1
 2/2011 AMC CEF COT TET R + + D N FII I1
 12/2007 AMC CEF COT CIP TET R + + B1 539 B/O I1
 9/2011 AMC CEF COT CIP TET GEN S +  B1 23 FII FIB
 9/2011 AMC CEF COT TET R + + B1 101 I1
0 3/2002 AMC CEF COT CIP TET R + + B2 167 FII FIA I1
1a 2/2010 AMC CEF COT TET R +  D 10 
1b 8/2010 AMC CEF TET R +  D 372 
2 7/2006 AMC CEF COT TET GEN S  n/d D 372 I2
3 8/2009 AMC COT CIP TET S  n/d A 10 FII FIA
4 8/2008 AMC COT CIP TET S  n/d A 10 
5 4/2009 AMC CEF COT CIP TET S  n/d A 998 
6a 4/2011 AMC CEF CIP TET GEN R  n/d B1 23 FII B/O
6b 5/2011 AMC COT CIP TET GEN S  n/d B2 23 FII FIB
stance pattern identiﬁes antimicrobials to which organisms were resistant: AMC = Amoxicillin clavulanate; CEF = Cephalexin; COT = co-trimoxazole;
 ciproﬂoxacin; TET = tetracycline; GEN = gentamicin. 3rd Gen identiﬁes which organisms were resistant (R) or sensitive (S) to the 3rd generation
alosporin cefotaxime. AmpC Pheno identiﬁes which isolates were positive or negative for AmpC on the 4 disc phenotypic test. AmpC PCR identiﬁes
e isolates where plasmid associated AmpC genes could be identiﬁed by PCR (n/d designates not done), Phylo represents phylogenetic group, STesents sequence type and N represents a novel ST type.
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PCR-based phylogenetic grouping was performed to
assign the isolates to one of 4 phylogenetic groups, namely
A, B1, B2 or D. Phylotypes A and B1 are considered to be
associated with commensal status or intestinal patho-
types, while B2 and D are more commonly associated with
strains causing extraintestinal infections (Tenaillon et al.,
2010). Among the susceptible isolates B2 was the
predominant phylogenetic group (10 isolates, 67%) with
no isolates in group A, 2 isolates (13%) in the B1 grouping
and 3 isolates (20%) in group D. In contrast, the MDR group
showed a more even distribution among all 4 phylogenetic
groups (1 isolate could not be typed), with B2 comprising
the smallest category. The distribution for A, B1, B2 or D
was 28%, 22%, 11% and 33% respectively. The proportion of
MDR isolates identiﬁed as phylotype B2 differed signiﬁ-
cantly from the proportion of susceptible isolates identi-
ﬁed as B2 (P < 0.001).
MLST identiﬁed 18 ST types among the E. coli isolates.
Within the MDR group these were: ST10 (n = 4); ST 23
(n = 3); ST372 (n = 2); ST46 (n = 1); ST744 (n = 1); ST648
(n = 1); ST963 (n = 1); ST539 (n = 1); ST101 (n = 1); ST167
(n = 1); and ST 998 (n = 1). The two MDR isolates belonging
to phylogenetic group B2 belonged to ST types 167 and 23.
The overall association of ST type and phylogenetic group
is listed in Table 1. Within the susceptible group ST types
identiﬁed were: ST73 (n = 4); ST12 (n = 2); ST641 (n = 1); ST
127 (n = 1); ST10 (n = 1); ST625 (n = 1); ST929 (n = 1); and
ST3005 (n = 1). A total of 3 isolates from the susceptible
group and 1 from the MDR group did not map to existing ST
types. None of the isolates belonged to ST131.
3.4. Identibac1 microarray analysis
A panel of 11 speciﬁc probes was extracted from a much
larger panel. These represent probes for which any isolate,
either susceptible or MDR, demonstrated a positive result.
The full list of probes against which isolates were tested
can be found in the supplementary materials.
The virulence marker panel results are summarized in
Table 3. Although the number of isolates examined was
limited, there were signiﬁcantly higher (P < 0.05) levels of
carriage demonstrated for 7/11 speciﬁc virulence markers
in the susceptible group compared to the MDR group.
3.5. Plasmid replicon typing
In the susceptible group (Table 2) plasmid replicons
could not be identiﬁed in 5 of the isolates. In the remaining
10 isolates, 6 isolates had 2 or more replicons and 4 isolates
carried single replicons. The FII replicon was present in 5
isolates and the FIB replicon was present in 4 isolates.
Overall 8 different replicon types were identiﬁed in this
group. In the MDR group (Table 1), plasmid replicons could
not be identiﬁed in 4 of the isolates. A total of 12 of the
remaining 14 carried 2 or more replicons and only 2
isolates carried single replicons. The FII replicon was
present in 11 isolates and the I1 replicon was present in 9
isolates. A total of 6 isolates carried the FII and I1 replicons
genotypically positive for pAmpC). Overall 6 different
replicon types were identiﬁed in this group.
4. Discussion
These ﬁndings demonstrate clinically signiﬁcant MDR
E. coli in canine urinary tract infections. The antibiogram
phenotype of isolates (Table 1.) shows that treatment
options are limited. All MDR isolates were resistant to the
recommended ﬁrst line treatment amoxicillin clavulanate
and more than half of the isolates were resistant to
ﬂuoroquinolones, a third line option (Weese et al., 2011).
MDR strains were analyzed in some detail. Comparisons
were made to a susceptible group of canine UTI isolates
from the same locality and indirectly to signiﬁcant human
clonal lineages. The latter is particularly important in light
of concerns regarding the transfer of organisms between
humans and domestic animals, and the potential for either
to act as a reservoir of infection for the other.
AmpC rather than ESBL-producing E. coli were com-
monly identiﬁed among the MDR isolates. This is inter-
esting because, in human UTIs associated with MDR E. coli,
ESBLs (particularly the CTX-M group) seem to be the
predominant enzymes responsible for broad-spectrum
resistance to b-lactams. Although this study has a low
number of isolates, other studies have also identiﬁed the
presence of AmpC producing E. coli in dogs associated with
both faecal carriage and clinical disease (Damborg et al.,
2011; Dierikx et al., 2012; Murphy et al., 2009; Shaheen
et al., 2011; Sidjabat et al., 2006; Tamang et al., 2012;
Wedley et al., 2011). Furthermore, routine screening in our
laboratory has continued to identify AmpC-producing
isolates causing urinary tract infection (10 isolates from
January 2012 to November 2013). Although this represents
a relatively low local incidence, these cases are still
clinically signiﬁcant and therapeutically challenging.
The phylogenetic proﬁle differed between the two
groups of isolates. The susceptible group of UTI isolates
predominantly belonged to the B2 phylogenetic group, as
Table 2
Summary of phylogenetic group and replicon type of the susceptible
urinary tract isolates.
Isolate Isolation date (month/year) Phylo ST Replicon type
S1 1/2003 B2 73 –
S2 10/2011 B2 73 –
S3 11/2001 B2 12 –
S4 11/2001 B2 73 –
S5 11/2001 B2 N –
S6 1/2001 B1 641 X1
S7 10/2002 B2 12 I2 R
S8 1/2003 D N FIA
S9 1/2003 B2 127 FIB
S10 12/2011 B2 10 FII
S11 12/2000 B2 73 FII FIB
S12 10/2011 D N FII FIB
S13 1/2002 D 625 FII FIB B/O
S14 8/2001 B2 929 FII I1
S15 9/2001 B1 3005 B/O I1
Phylo represents phylogenetic group, ST represents sequence type and N
represents novel sequence types.predicted from previous studies in humans and dogstogether (these 6 isolates were all phenotypically and
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1). The MDR group meanwhile demonstrated a more
n distribution across all four phylo-groups, with
iﬁcantly less representation of the B2 phylo-group. It
orth noting that a more recent methodology has been
e to assign E. coli to 8 rather than 4 phylo-groups
rmont et al., 2013), which could have altered the
ﬁle of the isolates in this study, and future work should
ploy the revised methodology to provide greater detail
 depth of characterization. In the context of the results
 this study, isolates already assigned to B1 or B2 would
unlikely to change classiﬁcation, so the difference
ween groups in the proportions of isolates in phylotype
should still be valid.
The virulence marker proﬁle also differed between the
 groups, suggesting a reduced virulence genotype in
 MDR isolates compared to the susceptible ones.
vious studies have indicated that, in MDR isolates
ociated with UTI in both humans and dogs, there may be
ift away from the dominance of the B2 phylogenetic
up and a decrease in certain virulence genes (Moreno
l., 2006; Vila et al., 2002). The reason for this pattern is
lear. Other researchers have speculated that less
pathogenic phylogenetic groups are more receptive to
the acquisition of the MDR phenotype (Johnson et al.,
2004), or that acquisition of the MDR phenotype results in
a trade off, with a loss of virulence traits. Whatever the
order of events, it would seem logical that less pathogenic
phylogenetic groups, with an MDR phenotype, would
require certain conditions under which to cause clinical
disease.
Sequence typing did not provide evidence for clonal
spread of isolates in either group. Considering the
extended sampling time this is probably not surprising.
More pertinent perhaps was the fact that ST131 was not
identiﬁed amongst any of our isolates. The O25b-
ST131clonal lineage is one of the most important
uropathogenic E. coli groups in humans. It belongs to the
B2 phylogenetic group, is multidrug-resistant (almost
always resistant to the ﬂuoroquinolones and often
resistant to 3rd generation cephalosporins), is often, but
not always, an ESBL producer (CTXM-15) and is highly
virulent (Oteo et al., 2010; Thompson et al., 2011). Total
reports of ST131 in domestic animals are still extremely
low and, although there is some support for interspecies
transfer of ST131, it is unclear if animals are a major
le 3
tiﬁcation of virulence markers in the MDR and susceptible E. coli isolates. X indicates presence of the gene.
late Phyl ireA iroN iss mchB mchC mchF mcm perA prfB senB sfaS
a a a a a a a
 A
 n/t
 A X X
 D X
 D
 D
 B1
 B1 X X X X X X
 B1 X X X X X
0 B2
1a D
1b D
2 D X
3 A X X
4 A
5 A
6a B1
6b B2 X X X X X
 B2 X X X X X X X
 B2 X X X X X X X X
 B2 X X X X X X X X
 B2 X X X X X X X
 B2 X X X X X X X X
 B1 X X X X X X
 B2 X X X X X X
 D X X X X X
 B2 X X X X X X
0 B2 X X X X X X X X X X X
1 B2
2 D X X X X
3 D X X X X X
4 B2 X X X X X X X X X
5 B1
DR isolate; S = susceptible isolate; Phyl = phylogroup; ireA = siderophore receptor; iroN = enterobactin siderophore receptor; iss = increased serum
ival; mchB = microcin H47 part of colicin H; mchC = MchC protein; mchF = ABC transporter protein; mcm = microcin M part of colicin H; perA = EPEC
erence factor; prfB = P-related ﬁmbriae regulatory gene; senB = plasmid encoded enterotoxin; sfaS = S ﬁmbriae minor subunit.
Identiﬁes signiﬁcant difference for MDR versus susceptible.
S. Wagner et al. / Veterinary Microbiology 169 (2014) 171–178176reservoir or incidental host of this ExPEC clonal lineage, or
indeed if humans act as an animal reservoir (Platell et al.,
2011). Certainly within the limitations of our study we
found no evidence for this.
One MDR isolate (R4) was typed as ST648 phylogenetic
group D. Strains of this clonal lineage that carry ESBLs, have
been associated with bacteraemias in human patients in
the Netherlands and NDM carbapenamases in human
patients in the United Kingdom and Pakistan (Tamang
et al., 2012).
Plasmid replicon typing was performed in order to
establish the range and diversity of plasmids amongst both
the MDR and susceptible isolates. Most of the plasmid
replicons correspond to incompatibility groups. In the
susceptible group replicon types could not be assigned to 5
of the isolates. This is perhaps not surprising, as the assay is
designed to detect resistance plasmids. In the MDR group
there were 4 isolates that were not assigned replicon types.
Interestingly 2 of these (R11a and b) were phenotypically
AmpC-producing, but it was not possible to detect
plasmid-associated genes. We speculate that AmpC
production in these isolates could be attributed to
chromosomal mutations in the ampC promoter. Further
analysis of these isolates will be required to conﬁrm this. In
the remainder of the MDR isolates the FII and I1 replicon
types were the most highly represented. We observed a
cluster comprising 6 isolates (R1–R6 Table 1) all AmpC-
producing and carrying Inc FII/IncI1 plasmids. Since IncFII
and IncI1 plasmids are two of a number of plasmid types
that are particularly successful in their ability to spread
multidrug resistance (Carattoli, 2011), further character-
ization and comparison of the plasmids from these isolates
would be of particular interest.
With the exception of one case for which we have no
history, all cases caused by MDR E. coli had underlying
disease involving suppression of the immune system (e.g.
hyperadrenocorticism, cancer chemotherapy), an anato-
mical abnormality of the genitourinary tract (e.g. detrusor
muscle atony, ectopic ureters), and/or a history of prior
antimicrobial treatment. Clinical details are summarized
in Table 4. This is not a surprising ﬁnding since it can be
envisaged that such factors will increase the potential of
isolates, which we speculate may be less virulent, to cause
clinical disease. What will be of interest is to follow the
natural history of infections caused by these organisms in
companion animals. It is highly probable that future
changes in the epidemiology of MDR E. coli infections in
dogs, will reﬂect those seen in the human population,
where there has been a shift from hospital-acquired
infection, analogous to what we have observed in this
study in dogs, to a community-acquired infection, where
they are associated with uncomplicated urinary tract
disease.
The main limitations of this study are the low number
of MDR isolates, and the relatively extended time over
which samples were collected. However, this reﬂects the
relative scarcity of such MDR isolates associated with
routine community-acquired canine urinary tract infec-
tions tested over the last decade at our laboratory, with the
majority of the MDR isolates arising from more complex
clinical cases at the small animal hospital.
5. Conclusion
MDR E. coli are a cause of a small but clinically
signiﬁcant number of urinary tract infections in dogs
serviced by the veterinary microbiology service at
Edinburgh University.
Broad-spectrum b-lactamase production is an impor-
tant resistance mechanism and, unlike in human infec-
tions, AmpC rather than ESBL production predominates.
This may reﬂect the gut carriage of AmpC E. coli in the dog.
Amongst our isolates MDR E. coli are skewed towards less
pathogenic phylogenetic groups and have a reduced
virulence genotype. The variety of ST types does not
support clonal spread; horizontal transfer of certain
plasmid types may be a more important mechanism for
the transmission of the MDR phenotype, judging by the
frequency of the IncFII and IncI1 plasmid types. Most
importantly, ST type analysis of both susceptible and MDR
Table 4
Clinical summary of the cases from which MDR E. coli were isolated.
Isolate Breed Age (years) Summary of clinical details
R1 Dachshund 10 Surgery to treat intervertebral disc prolapse. Amoxicillin/clavulanate used for surgical prophylaxis.
R2 Weimeraner 9 Prostatic abscess. Surgical drainage and antibiotics (enroﬂoxacin and clindamycin).
R4 Cocker Spaniel 4 Immune mediated haemolytic anaemia, which was treated with immunosuppressant drugs.
R5 Cross breed 11 Hyperadrenocorticism. Amoxicillin/clavulanate administered for several months to manage
concurrent liver disease.
R6 Boxer 9 Multiple mast cell tumours. Resection followed by cancer chemotherapy.
R7 Schnauzer 6 Mast cell tumour. Surgical management followed by cancer chemotherapy.
R8 Labrador 10 Surgery to resect intestinal adenocarcinoma. Post surgery developed pneumonia and treated with
multiple antibiotics.
R9 Collie 10 Diabetes mellitus poorly controlled.
R10 German Shepherd 8 Prostatic infection and a perineal hernia accompanied by recurrent cystitis.
R11 Bouvier de Flandres 6 Placement of a gastrostomy tube. The stoma became infected requiring antimicrobials.
Subsequently the dog developed recurrent urinary tract infections.
R12 Bearded Collie 1 Pyelonephritis. Initially treated with amoxicillin/clavulanate.
R13 Cocker Spaniel 7 Pancreatitis
R14 Golden Retriever 5 Ectopic ureters possibly acting as a predisposing factor for urinary tract infection.
R15 Yorkshire Terrier 11 Concurrent urolithiasis.
R16 Boxer cross 7 Detrusor muscle atony decreasing the ability to empty the bladder during urination.
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